Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

Selenium and vitamin E supplements do not prevent prostate cancer

Initial, independent review of study data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT), funded by the National Cancer Institute (NCI) and other institutes that comprise the National Institutes of Health shows that selenium and vitamin E supplements, taken either alone or together, did not prevent prostate cancer.

28 Oct 2008

Vitamin E and selenium do not prevent prostate cancer

A major study on whether vitamin E and selenium prevent prostate cancer has been stopped because the supplements are not effective and also because there is a suspicion of a risk.

28 Oct 2008

Sensitive ultrasound to spot early-stage cancer

European researchers have developed highly sensitive ultrasound equipment that can detect tiny quantities of reflective microbubbles engineered to stick to specific tumour cells. The technique should pick up tumours early and improve patients' chances of survival.

26 Oct 2008

Scientists grow prostates from mouse stem cells

A team of molecular biologists in the U.S. have grown complete prostates derived from stem cells in the prostates of mice and they say the experiment represents a big step towards regenerating organs from a patients' own cells.

23 Oct 2008

Chance of dying from cancer before the age of 84 is falling

The chance of dying from cancer before the age of 84 is becoming much smaller for most types of cancer and should continue falling over the next 20 years according to a new study from Cancer Research UK.

19 Oct 2008

OncoGenex achieves key regulatory milestone for lead product candidate

OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).

13 Oct 2008

FDA approves Rapaflo for treatment of symptoms due to benign prostatic hyperplasia

The U.S. Food and Drug Administration today approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia (BPH), a condition also known as an enlarged prostate.

12 Oct 2008

Lilly to acquire ImClone Systems for $6.5 billion

Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.

6 Oct 2008

Weight linked to prostate cancer death

New research, funded in part by the Canadian Cancer Society, shows that men suffering from prostate cancer are up to 2 1/2 times more at risk of dying from the disease if they are overweight or obese. The men who participated in the study had been weighed prior to being diagnosed with prostate cancer.

5 Oct 2008

New advance in robotic prostate surgery

To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy -- the surgical removal of the prostate -- eliminates the pain and discomfort associated with the standard catheter.

2 Oct 2008

Raised risk of prostate cancer in Black men

Black men living in England are three times more likely to get prostate cancer than White men and tend to be diagnosed five years younger, researchers have found.

2 Oct 2008

Gap in black, white new cancer diagnoses narrowing in Missouri; mortality rate gap falling more slowly, study finds

The gap between blacks and whites in Missouri for newly diagnosed cancers is narrowing in part because of an overall decline in smoking and an increase in cancer screenings, according to a study to be published early next year in the journal Missouri Medicine, the AP/St. Louis Post-Dispatch reports.

29 Sep 2008

Prostate cancer genes behave like those in embryo

Gene activity in prostate cancer is reminiscent of that in the developing fetal prostate, providing further evidence that all cancers are not equal, Johns Hopkins researchers report. The finding could help scientists investigate how to manipulate the genetic program to fight a disease whose biology remains poorly understood despite more than half a century of investigation.

16 Sep 2008

Novel treatment for prostate cancer

Scientists at Sunnybrook Research Institute (SRI) are developing and commercializing a promising novel therapy for the treatment of prostate cancer that may offer patients a faster and more precise treatment than existing clinical alternatives, with fewer side effects.

15 Sep 2008

Lung cancer in non-smokers is sixth biggest cancer killer

While lung cancer in smokers and former smokers is the biggest cancer killer by far, lung cancer in people who have never smoked is -- by itself -- the sixth biggest cancer killer in the United States.

15 Sep 2008

More prostate cancer but fewer deaths

A major study by researchers from the Cancer Council Australia has found that even though more men are being diagnosed with prostate cancer, fewer are dying from the disease.

15 Sep 2008

Anti-inflammatory drugs may mask prostate cancer marker

Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, may reduce serum levels of the prostate biomarker, PSA (prostate specific antigen), and hence may alter the detection of prostate cancer in individuals who take these medications.

14 Sep 2008

Common painkillers lower levels of prostate cancer biomarker

Common painkillers like aspirin and ibuprofen appear to lower a man's PSA level, the blood biomarker widely used by physicians to help gauge whether a man is at risk of prostate cancer.

9 Sep 2008